Heidi Ko, Medical Director, Medical Affairs at Labcorp Drug Development, shared on LinkedIn:
“MBCC26 is officially underway, and Day 2 is off to a great start!
A standout early session by Dr. Parsons from Fred Hutch on the practical use of ctDNA in early breast cancer, clearly breaking down how to interpret and act on results in real‑world practice.
A thoughtful, balanced discussion highlighting both the promise of ctDNA and the need for fit‑for‑purpose testing as the evidence continues to evolve.”
Other articles featuring Heidi Ko on OncoDaily.
